People · Operator
Named in public records as an officer, director or promoter · active 2015–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2018 |
| Velicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $39.9M | $204.0M | 2015 |
Scott Morenstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Morenstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Walker | 1 | 16 |
| David Hirsch | 1 | 16 |
| Stephen Tullman | 1 | 7 |
| Craig Gordon | 1 | 6 |
| Gregory Mayes | 1 | 5 |
| NICOLE VITULLO | 1 | 4 |
| Douglas Gessl | 1 | 4 |
| James C. Walker | 1 | 3 |
| Scott S. Morenstein | 1 | 3 |
| Iyona Rajkomar | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| Aidan King | 1 | 3 |
| DAVID CANNER | 1 | 2 |
| Idean Marvasty | 1 | 2 |
| Patrick Higgins | 1 | 2 |
| Cory Freedman | 1 | 1 |
| James Bennethum | 1 | 1 |
| Tamra Adams | 1 | 1 |
| Abel De La Rosa | 1 | 1 |
| Douglas Mayers | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.